Flavonoids Docked into Several Target Proteins Associated with Cancer: A Molecular Docking Study
doi.org/10.26538/tjnpr/v5i12.2
Keywords:
Flavonoids, Docking, DR4, DR5, EGFR, FarnesyltransferaseAbstract
The emergence of new drug discovery for cancer treatment is vital and continuously gaining global attention. Although the discovery and development of a new drug takes a long time, the efforts should be retained. Successful findings could be repeated for cancer therapy from natural compounds by investigating flavonoids from molecular docking as the initial study towards the drug development process. Flavonoids derived from plants are believed to have the capability to interact with cancer-related proteins. The present study aims to identify the most favourable cancer-related proteins to be targeted by selected flavonoids through molecular docking simulation. In this study, selected flavonoids from different classes have been docked with several targeted proteins which are involved in cell death, survival, and proliferation, such as death receptors 4 and 5 (DR4 and DR5), epidermal growth factor receptor EGFR) and farnesyltransferase (FTase). Of all the proteins tested for docking simulation, EGFR protein is among the best-targeted proteins compared to other proteins with the lowest binding energies for each flavonoid, ranging from -9.1 to -8.4 kcalmol-1 . Meanwhile, myricetin (7) exhibited the strongest binding affinity for three proteins, including EGFR, FTase and DR5. On the other hand, DR4 protein has shown interaction favourably with flavone (5) with the binding affinity of -8.0 kcalmol-1 . The docking results suggest that the selected flavonoids generally have good binding affinities and interactions with cancer-target proteins, which could be proposed as inhibitors of targeted-proteins in cancer therapy.
References
Karak P. Biological activities of flavonoids: an overview. Int J Pharm Sci Res. 2019; 10(4):1567-1574.
Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J. Flavonoids as anticancer agents. Nutr. 2020; 12(2):457.
Abotaleb M, Samuel SM, Varghese E, Varghese S, Kubatka P, Liskova A, Busselberg D. Flavonoids in Cancer and Apoptosis. Cancers. 2018; 11(1):28.
Panche AN, Diwan AD, Chandra SR. Flavonoids: An overview. J Nutr Sci. 2016; 5:e47.
Durazzo A, Lucarini M, Souto EB, Cicala C, Caiazzo E, Izzo AA, Novellino E, Santini A. Polyphenols: A concise overview on the chemistry, occurrence, and human health. Phytother Res. 2019; 33(9):2221-2243.
Papadopoulou A and Frazier RA. Characterization of protein–polyphenol interactions. Trends Food Sci Technol. 2004; 15(3-4):186-190.
Annibaldi A and Walczak H. Death Receptors and Their Ligands in Inflammatory Disease and Cancer. Cold Spring Harbor Perspectives in Biology. 2020; 12(9):a036384.
Micheau O. Regulation of TNF-related apoptosis-inducing ligand signaling by glycosylation. Int J Mol Sci. 2018; 19(3):715.
Yu R, Albarenque SM, Cool RH, Quax WJ, Mohr A, Zwacka RM.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer. Cancer BiolTher. 2014; 15(12):1658-1666.
Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I, Hussain AF. Molecular targeting therapy against EGFR family in breast cancer: Progress and future potentials. Cancers. 2019; 11(12):1826.
Momeny M, Esmaeili F, Hamzehlou S, Yousefi H, Javadikooshesh S, Vahdatirad V, Alishahi Z, Mousavipak SH, Bashash D, Dehpour AR, Tavangar SM. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells. Cell Oncol. 2019; 42(4):491-504.
Wang Z. ErbB Receptors and Cancer. In: Wang Z (Eds.). ErbB Receptor Signaling. Methods in Molecular Biology. New York: Humana Press; 2017. 3-35 p
J Brock E, Ji K, Reiners J, Mattingly R. How to target activated Ras proteins: direct inhibition vs. induced mislocalization. Mini Rev Med Chem. 2016; 16(5):358-369.
Audagnotto M and Dal Peraro M. Protein post-translational modifications: In silico prediction tools and molecular modeling. Comput Struct Biotechnol J. 2017; 15(2017):307-319.
Dai X, Sun Y, Zhang T, Ming Y, Hongwei G. An overview on natural farnesyltransferase inhibitors for efficient cancer therapy. J Enzyme Inhib Med Chem. 2020; 35(1):1027-1044.
Simanshu DK, Nissley DV, McCormick F. RAS proteins and their regulators in human disease. Cell. 2017; 170(1):17-33.
Oikonomou E, Koustas E, Goulielmaki M, Pintzas A. BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications. Oncotarget. 2014; 5(23):11752-11777.
Pinzi L and Rastelli G. Molecular docking: shifting paradigms in drug discovery. Int J Mol Sci. 2019; 20(18):4331.
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE. PubChem in 2021: new data content and improved web interfaces. Nucleic Acids Res. 2019; 49(D1):D1388-D1395.
Systèmes D. Biovia, discovery studio modeling environment. Dassault Systèmes Biovia: San Diego, CA, USA. 2016.
Ramamurthy V, Yamniuk AP, Lawrence EJ, Yong W, Schneeweis LA, Cheng L, Murdock M, Corbett MJ, Doyle ML, Sheriff S. The structure of the death receptor 4–TNF-related apoptosis-inducing ligand (DR4–TRAIL) complex. Acta Cryst F, Struct Biolog Cryst Commun. 2015; 1(10):1273-1281.
Wajant H. Molecular mode of action of TRAIL receptor agonists—common principles and their translational exploitation. Cancers. 2019; 11(7):954.
Sogabe S, Kawakita Y, Igaki S, Iwata H, Miki H, Cary DR, Takagi T, Takagi S, Ohta Y, Ishikawa T. Structure-based approach for the discovery of pyrrolo [3, 2-d] pyrimidine-based EGFR T790M/L858R mutant inhibitors. ACS Med Chem Lett. 2013; 4(2):201-205.
Reid TS and Beese LS. Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. Biochem. 2004; 43(22):6877-6884.
Oleg T and Arthur JO. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading.J Comput Chem. 2010;31(2):455-461.
Rymbai E, Sugumar D, Saravanan J, Divakar S. Ropinirole, a potential drug for systematic repositioning based on side effect profile for management and treatment of Breast Cancer. Med Hypotheses. 2020; 144(2020):110156.
Liu Y, Zheng H, Li Q, Li S, Lai H, Song E, Li D, Chen J. Discovery of CCL18 antagonist blocking breast cancer metastasis. Clin Exp Metastasis. 2019; 36(3):243-255.
Ye H, Zhou Q, Zheng S, Li G, Lin Q, Wei L, Fu Z, Zhang B, Liu Y, Li Z, Chen R. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Cell Death Dis. 2018; 9(5):1-19.
Das S, Tripathi N, Siddharth S, Nayak A, Nayak D, Sethy C, Bharatam PV, Kundu CN. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Apoptosis. 2017; 22(10):1205-1224.
Kaboli PJ, Salimian F, Aghapour S, Xiang S, Zhao Q, Li M, Wu X, Du F, Zhao Y, Shen J, Cho CH. Akt-targeted therapy as a promising strategy to overcome drug resistance in breast cancer–A comprehensive review from chemotherapy to immunotherapy. Pharmacol. Res. 2020; 156(2020):104806.
Choudhury P, Barua A, Roy A, Pattanayak R, Bhattacharyya M, Saha P. Eugenol restricts Cancer Stem Cell population by degradation ofcatenin via N-terminal Ser37 phosphorylation-an in vivo and in vitro experimental evaluation. Chem Biol Interact. 2020; 316(2020):108938.
Rajendran P, Maheshwari U, Muthukrishnan A, Muthuswamy R, Anand K, Ravindran B, Dhanaraj P, Balamuralikrishnan B, Chang SW, Chung WJ. Myricetin: versatile plant-based flavonoid for cancer treatment by inducing cell cycle arrest and ROS–reliant mitochondria-facilitated apoptosis in A549 lung cancer cells and in silico prediction. Mol Cell Biochem. 2020; 476(1):57-68.
Rosenkranz AA and Slastnikova TA. Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. Biochem. 2020; 85(9):967-993.
Maennling AE, Tur MK, Niebert M, Klockenbring T, Zeppernick F, Gattenlöhner S, Meinhold-Heerlein I, Hussain AF. Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials. Cancers. 2019; 11(12):1826.
Sun Q, Ming L, Thomas SM, Wang Y, Chen ZG, Ferris RL, Grandis JR, Zhang L, Yu J. PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells. Oncogene. 2009; 28(24):2348-2357.
Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci. 2009; 106(46):19503-19508.
Fleming IN, Hogben M, Frame S, McClue SJ, Green SR. Synergistic inhibition of ErbB signaling by combined treatment with seliciclib and ErbB- targeting agents. Clin Cancer Res. 2008; 14(3):4326-4335.
Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Christensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. 2003; 63(17):5462-5469.
Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D, Parsons C, Reiss K, Zabaleta J, Qin Z. Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood Adv. 2015; 126(26):2821-2831.
Sousa SF, Fernandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem. 2008; 15(15):1478-1492.
Ashok S, Hildebrandt ER, Ruiz CS, Hardgrove DS, Coreno DW, Schmidt WK,Hougland JL. Protein farnesyltransferase catalyzes unanticipated farnesylation and geranylgeranylation of shortened target sequences. Biochem. 2020; 59(11):1149-1162.
Zhou J, Vos CC, Gjyrezi A, Yoshida M, Khuri FR, Tamanoi F, Giannakakou P. The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner. J Biol Chem. 2009; 284(15):9648-9655.
Jin Z and El-Deiry WS. Overview of cell death signalling pathways. Cancer Biol Ther. 2005; 4(2):147-171.
Falschlehner C, Ganten TM, Koschny R, Schaefer U, Walczak H.TRAIL and Other TRAIL Receptor Agonists as Novel Cancer Therapeutics. In: Grewal IS(Eds.). Therapeutic Targets of the TNF Superfamily. Advances in Experimental Medicine and Biology.New York: Springer; 2009. 195-206 p
Ngo HX and Garneau-Tsodikova S. What are the drugs of the future? Med Chem Comm. 2018; 9(5):757-757
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
